Advancing computerized cognitive training for early Alzheimer's disease in a Covid-19 pandemic and post-pandemic world
Kaylee A. Bodner, Terry E. Goldberg, D. P. Devanand, P. Murali Doraiswamy
Abstract
Worldwide, some 40 million adults have Alzheimer's disease (AD) and several hundred million may be at elevated risk for AD by virtue of genetic risk, cerebrovascular disease, comorbid illnesses such as diabetes or depression, mild cognitive impairment (MCI) and/or silent buildup of cortical AD pathology (1). Despite extensive research, there are no pharmacological treatments with more than minimal efficacy for mild AD, and prevention strategies are not established.
§ The Valyu brief
Reading the full paper and taking notes. This takes a few seconds…
§ Ask this paper
Ask a question about this paper
Valyu reads the full text and answers from what the paper actually says.
Searching the other archives…